1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in Japan, August 2019

Cancer Analysis & Statistics in Japan, August 2019

1-30 of about 300 reports

Japan Tumor Marker Testing Analyzers and Reagents Market, 2019-2023: Supplier Shares and Sales Segment Forecasts by Product--Competitive Intelligence, Technology and Instrumentation Review, Opportunities for Suppliers

Japan Tumor Marker Testing Analyzers and Reagents Market, 2019-2023: Supplier Shares and Sales Segment Forecasts by Product--Competitive Intelligence, Technology and Instrumentation Review, Opportunities for Suppliers

  • € 4297
  • Industry report
  • July 2019

Japan Tumor Marker Testing Analyzers and Reagents Market, 2019-2023: Supplier Shares and Sales Segment Forecasts by Product--Competitive Intelligence, Technology and Instrumentation Review, Opportunities ...

  • Industries : Cancer
  • Countries : Japan
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

  • € 4166
  • Industry report
  • July 2019

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends and opportunities in the nearly $1bn Prostate Cancer Diagnostics and ...

  • Industries : Cancer, Pathology, Diagnostics
  • Countries : United States, Japan
Japan Hospital Tumor Marker Testing Market, 2019-2023: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review

Japan Hospital Tumor Marker Testing Market, 2019-2023: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review

  • € 3070
  • Industry report
  • May 2019

Japan Hospital Tumor Marker Testing Market, 2019-2023: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation ReviewThis new report contains 537 pages, 42 tables, and presents ...

  • Industries : Cancer, Pathology
  • Countries : Japan
Japan Hospital Tumor Marker Testing Market, 2019-2023: Supplier Shares and Strategies, Test Volume and Sales Forecasts, Emerging Technologies, Instrumentation and Opportunities

Japan Hospital Tumor Marker Testing Market, 2019-2023: Supplier Shares and Strategies, Test Volume and Sales Forecasts, Emerging Technologies, Instrumentation and Opportunities

  • € 3070
  • Industry report
  • May 2019

Japan Hospital Tumor Marker Testing Market, 2019-2023: Supplier Shares and Strategies, Test Volume and Sales Forecasts, Emerging Technologies, Instrumentation and OpportunitiesThis new report from VPGMarketResearch ...

  • Industries : Cancer, Pathology
  • Countries : Japan
Japan Hospital Cancer Diagnostics Market, 2019-2023: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review

Japan Hospital Cancer Diagnostics Market, 2019-2023: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review

  • € 2806
  • Industry report
  • May 2019

Japan Hospital Cancer Diagnostics Market, 2019-2023: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation ReviewThis new report contains 537 pages, 42 tables, and presents a ...

  • Industries : Cancer, Pathology
  • Countries : Japan
Japan Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers, 2019-2023

Japan Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers, 2019-2023

  • € 2149
  • Industry report
  • July 2019

Japan Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers, 2019-2023HighlightsComprehensive 590-page ...

  • Industries : Cancer
  • Countries : Japan
Global DNA Probes-Based Diagnostics Industry

Global DNA Probes-Based Diagnostics Industry

  • € 4911
  • Industry report
  • May 2019

This report analyzes the worldwide markets for DNA Probes-Based Diagnostics in US$ Million by the following Application Areas: Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, ...

  • Industries : Pathology, Cancer, Genomics Proteomics and Enabling Technology, Diagnostics, Chronic Disease
  • Countries : World, APAC, Japan, Europe, United States, Canada
2019 Japan Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

2019 Japan Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

  • € 2149
  • Industry report
  • April 2019

2019 Japan Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for SuppliersHighlightsComprehensive 590-page ...

  • Industries : Cancer
  • Countries : Japan
Chemotherapy Induced Anemia - Pipeline Review, H1 2019

Chemotherapy Induced Anemia - Pipeline Review, H1 2019

  • € 1754
  • Company report
  • March 2019

Chemotherapy Induced Anemia - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2019, ...

  • Industries : Pathology, Therapy, Pharmaceutical, Oncology, Healthcare
  • Countries : United States, Japan, World
Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

  • € 9643
  • Industry report
  • March 2019

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027SummaryThe Multiple Myeloma (MM) market is expected to grow from $14.5bn in 2017 to $27.8bn by 2027 across the 8 major markets (US, France, ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, East Asia, China, Japan, World, North America
Multiple Myeloma: Epidemiology Forecast to 2027

Multiple Myeloma: Epidemiology Forecast to 2027

  • € 3504
  • Industry report
  • March 2019

Multiple Myeloma: Epidemiology Forecast to 2027SummaryMultiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C90.0) is a ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan
CB-839

CB-839

  • € 8770
  • Industry report
  • March 2019

Drug OverviewCancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Renal cell cancer (RCC) disease forecast and market analysis to 2038

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • € 19294
  • Industry report
  • March 2019

DISEASE OVERVIEWRenal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Afinitor

Afinitor

  • € 8770
  • Industry report
  • March 2019

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Lenvima

Lenvima

  • € 8770
  • Industry report
  • March 2019

Lenvima (lenvatinib; Eisai/Novartis/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Sutent

Sutent

  • € 8770
  • Industry report
  • March 2019

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth facto ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Votrient

Votrient

  • € 8770
  • Industry report
  • March 2019

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Avastin

Avastin

  • € 8770
  • Industry report
  • March 2019

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Nexavar

Nexavar

  • € 8770
  • Industry report
  • March 2019

Nexavar (sorafenib; Bayer/Amgen)  is a small molecule inhibitor that is currently the only targeted treatment available for first-line hepatocellular carcinoma patients.

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Inlyta

Inlyta

  • € 8770
  • Industry report
  • March 2019

Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Torisel

Torisel

  • € 8770
  • Industry report
  • March 2019

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Chimeric Antigen Receptor Cell Therapy

Chimeric Antigen Receptor Cell Therapy

  • € 7012
  • Industry report
  • February 2019

Chimeric Antigen Receptor Cell TherapySummaryChimeric Antigen Receptor (CAR) cell therapy is an Immuno-Oncology (IO) approach that has gained increasing momentum in the past few years.Despite having demonstrated ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Pharmaceutical
  • Countries : United States, Japan, Europe, World, North America
Gazyva

Gazyva

  • € 8770
  • Industry report
  • January 2019

Drug OverviewGazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union, Japan
Aliqopa

Aliqopa

  • € 8770
  • Industry report
  • January 2019

Drug OverviewAliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial fo ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Venclexta

Venclexta

  • € 8770
  • Industry report
  • January 2019

Drug OverviewVenclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins. This family of proteins is responsible for the regulation of cell death by eithe ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Rituxan

Rituxan

  • € 8770
  • Industry report
  • January 2019

Drug OverviewRituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) is a murine/human chimeric cluster of differentiation (CD)20-targeted monoclonal antibody that is indicated for the treatment of a numbe ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union, Japan
Treanda/Bendeka

Treanda/Bendeka

  • € 8770
  • Industry report
  • January 2019

Drug OverviewTreanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent. The exact mechanism of action of the drug is still not fully known, but it is a mechlorethamine derivative ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Imbruvica

Imbruvica

  • € 8770
  • Industry report
  • January 2019

Drug OverviewImbruvica (ibrutinib; AbbVie/Johnson and Johnson) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Kymriah

Kymriah

  • € 8770
  • Industry report
  • January 2019

Drug OverviewKymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union, Japan
Yescarta

Yescarta

  • € 8770
  • Industry report
  • January 2019

Drug OverviewYescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained ...

  • Industries : Medical Biotechnology, Cancer, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on